Literature DB >> 33429741

Comparison of the efficacy of rivaroxaban and dabigatran etexilate in preventing venous thrombosis after arthroplasty: A protocol of randomized controlled trial.

Runze Song1, Ruisheng Qu, Yu Wang, Dong Zhou, Anping Zhang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33429741      PMCID： PMC7793330          DOI： 10.1097/MD.0000000000023814

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN： 0025-7974            Impact factor:   1.817


× No keyword cloud information.
  12 in total

1.  AAOS clinical practice guideline: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty.

Authors:  Michael A Mont; Joshua J Jacobs
Journal:  J Am Acad Orthop Surg       Date:  2011-12       Impact factor: 3.020

2.  Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Yngve Falck-Ytter; Charles W Francis; Norman A Johanson; Catherine Curley; Ola E Dahl; Sam Schulman; Thomas L Ortel; Stephen G Pauker; Clifford W Colwell
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study.

Authors:  A G G Turpie; W D Fisher; K A Bauer; L M Kwong; M W Irwin; P Kälebo; F Misselwitz; M Gent
Journal:  J Thromb Haemost       Date:  2005-11       Impact factor: 5.824

4.  Epidemiology and risk factors for perioperative mortality after total hip and knee arthroplasty.

Authors:  Stavros G Memtsoudis; Matthias Pumberger; Yan Ma; Ya-Lin Chiu; Gerhard Fritsch; Peter Gerner; Lazaros Poultsides; Alejandro Gonzalez Della Valle
Journal:  J Orthop Res       Date:  2012-04-19       Impact factor: 3.494

5.  Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.

Authors:  B I Eriksson; O E Dahl; N Rosencher; A A Kurth; C N van Dijk; S P Frostick; P Kälebo; A V Christiansen; S Hantel; R Hettiarachchi; J Schnee; H R Büller
Journal:  J Thromb Haemost       Date:  2007-11       Impact factor: 5.824

Review 6.  Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  William H Geerts; Graham F Pineo; John A Heit; David Bergqvist; Michael R Lassen; Clifford W Colwell; Joel G Ray
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

7.  Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.

Authors:  Bengt I Eriksson; Lars C Borris; Richard J Friedman; Sylvia Haas; Menno V Huisman; Ajay K Kakkar; Tiemo J Bandel; Horst Beckmann; Eva Muehlhofer; Frank Misselwitz; William Geerts
Journal:  N Engl J Med       Date:  2008-06-26       Impact factor: 91.245

8.  The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans.

Authors:  Stefan Blech; Thomas Ebner; Eva Ludwig-Schwellinger; Joachim Stangier; Willy Roth
Journal:  Drug Metab Dispos       Date:  2007-11-15       Impact factor: 3.922

9.  Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.

Authors:  Sam Schulman; Ajay K Kakkar; Samuel Z Goldhaber; Sebastian Schellong; Henry Eriksson; Patrick Mismetti; Anita Vedel Christiansen; Jeffrey Friedman; Florence Le Maulf; Nuala Peter; Clive Kearon
Journal:  Circulation       Date:  2013-12-16       Impact factor: 29.690

10.  The effect of a new direct Factor Xa inhibitor on human osteoblasts: an in-vitro study comparing the effect of rivaroxaban with enoxaparin.

Authors:  Gandhi N Solayar; Pauline M Walsh; Kevin J Mulhall
Journal:  BMC Musculoskelet Disord       Date:  2011-10-28       Impact factor: 2.362
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.